The Centers for Disease Control and Prevention is assisting in a multistate investigation on the use of contaminated non-sterile ultrasound gel for ultrasound-guided percutaneous procedures. Reports of Paraburkholderia fungorum detected in blood cultures from patients across multiple health care facilities prompted the investigation, and the CDC said it was aware of 40 confirmed cases of the bacteria in four states and two other countries as of May 8. Tests found at least two contaminated products under the MediChoice and ClearImage brands that are manufactured by NEXT Medical Products Company. The CDC provided a series of recommendations for health care providers to ensure patient safety and prevent potential outbreaks.

Headline
The AHA has released a new issue brief designed to help hospitals and health systems strengthen disability competence and improve patient outcomes. The AHA is…
Headline
The Centers for Medicare & Medicaid Services Aug. 11 released a final rule that prohibits states from receiving federal matching funds for “sex-rejecting…
Headline
The Centers for Medicare & Medicaid Services today finalized a 2.3% payment update for long-term care hospitals for fiscal year 2027 relative to FY 2026.…
Headline
Following an introduction from Michelle Hood, AHA executive vice president and COO, moderator Chris DeRienzo, M.D., AHA senior vice president and chief…
Headline
During a panel discussion July 12 on scaling innovation, moderator Joy Rhoden, senior vice president and executive director of the AHA’s…
Headline
The AHA announced July 8 that Erie County Medical Center of Buffalo, N.Y., and the Geriatrics and Extended Care Hospice and Palliative Medicine Team of Orlando…